Emmaus Partners with US Bioservices to Offer SCD Patients New Treatment Adherence Program

Emmaus Partners with US Bioservices to Offer SCD Patients New Treatment Adherence Program
0
(0)

To help empower individuals living with sickle cell disease (SCD), biopharmaceutical company Emmaus Life Sciences has teamed up with national specialty pharmacy US Bioservices on a treatment adherence program for patients.

Through a team of clinicians, the new opt-in enhanced nursing program offers patients information and real-time assistance with their specific SCD therapy. In general, a treatment adherence program is a care system in which pharmacies have a more consultative role in helping patients to follow through with prescribed therapies. In this program, patients will be able to receive calls relating to their specific SCD therapy and work directly with clinicians.

“We believe this is an industry first for the SCD community and a truly unique tool and capability that will allow patients to stay informed about their disease as well as expand and improve their choices of medical management, resulting in improved adherence and outcomes,” Yutaka Niihara, MD, Emmaus chairman and CEO, said in a press release.

“This valuable program is another important part of our commitment to provide SCD patients with the full continuum of care.”

A leader in SCD treatment, Emmaus is the developer of Endari (L-glutamine), an oral therapy that increases the amount of free glutamine in the blood. That works to ultimately allow sickle-shaped red blood cells to regain the flexibility needed to travel through blood vessels and capillaries, carrying oxygen to tissues throughout the body. Sickle cell disease affects red blood cells with an abnormal version of the protein hemoglobin, causing its altered shape.

“Emmaus has always prioritized the needs and concerns of SCD patients and understands the importance of programs designed to continually improve the patient experience, assistance and relevant information,” added George Sekulich, Emmaus senior vice president of global commercialization.

“Providing patients with unencumbered access to our SCD drug Endari and resources to enhance their treatment experience has always been a core mission of Emmaus since our founding,” he said.

An AmerisourceBergen company, US Bioservices provides comprehensive clinical care to patients with chronic and complex disorders. According to the American Society of Hematology, between 70,000 and 100,000 U.S. residents have sickle cell disease.

In related news, Emmaus last month said it expects within the first quarter of this year to get initial purchase orders relating to Taiba Healthcare group’s early access program for Endari in some Middle East and North African nations. The region represents a significantly larger market for the treatment than the United States. Based in Oman, Taiba focuses on niche therapeutic segments, including rare diseases.

“In a relatively short period of time, taiba has become a valuable partner in bringing patients in the Middle East this much needed drug,” Sekulich said. “Through this partnership, we have already identified 40 patients and look forward to working with taiba to expand and increase access to patients in the entire MENA [Middle East and North Africa] region.”

“Our team has received positive feedback from HCPs [health care providers] across the territory who are excited to have L-glutamine as a valuable therapeutic option for the treatment of sickle cell disease patients,” said Dr. Saif Al-Hasani, Taiba’s CEO.

Mary M. Chapman began her professional career at United Press International, running both print and broadcast desks. She then became a Michigan correspondent for what is now Bloomberg BNA, where she mainly covered the automotive industry plus legal, tax and regulatory issues. A member of the Automotive Press Association and one of a relatively small number of women on the car beat, Chapman has discussed the automotive industry multiple times of National Public Radio, and in 2014 was selected as an honorary judge at the prestigious Cobble Beach Concours d’Elegance. She has written for numerous national outlets including Time, People, Al-Jazeera America, Fortune, Daily Beast, MSN.com, Newsweek, The Detroit News and Detroit Free Press. The winner of the Society of Professional Journalists award for outstanding reporting, Chapman has had dozens of articles in The New York Times, including two on the coveted front page. She has completed a manuscript about centenarian car enthusiast Margaret Dunning, titled “Belle of the Concours.”
Total Posts: 94
Margarida graduated with a BS in Health Sciences from the University of Lisbon and a MSc in Biotechnology from Instituto Superior Técnico (IST-UL). She worked as a molecular biologist research associate at a Cambridge UK-based biotech company that discovers and develops therapeutic, fully human monoclonal antibodies.
×
Mary M. Chapman began her professional career at United Press International, running both print and broadcast desks. She then became a Michigan correspondent for what is now Bloomberg BNA, where she mainly covered the automotive industry plus legal, tax and regulatory issues. A member of the Automotive Press Association and one of a relatively small number of women on the car beat, Chapman has discussed the automotive industry multiple times of National Public Radio, and in 2014 was selected as an honorary judge at the prestigious Cobble Beach Concours d’Elegance. She has written for numerous national outlets including Time, People, Al-Jazeera America, Fortune, Daily Beast, MSN.com, Newsweek, The Detroit News and Detroit Free Press. The winner of the Society of Professional Journalists award for outstanding reporting, Chapman has had dozens of articles in The New York Times, including two on the coveted front page. She has completed a manuscript about centenarian car enthusiast Margaret Dunning, titled “Belle of the Concours.”
Latest Posts
  • Covid-19 survey
  • GBT and COVID-19
  • upper GI bleeding risk

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?